1. Scrip
  2. >>R&D

Many New Frontiers Ahead For Regeneron

 
• By Jessica Merrill

Chief scientific officer George Yancopoulos talked to Scrip about the company’s plans to develop muscle-sparing weight loss drugs and Regeneron’s continued expansion into new areas.

Regeneron headquarters
Regeneron's Yancopoulos talked about development plans in an interview. • Source: Shutterstock

Regeneron Pharmaceuticals, Inc. is ready to jump straight into a Phase II study testing two potential muscle-sparing drugs for the treatment of obesity, with an eye on combination use with existing GLP-1 agonists, and is also studying a novel internally discovered target, GPR75, in preclinical development.

Key Takeaways

  • Regeneron is testing muscle-sparing drugs in combination with the GLP-1 agonist semaglutide.

  • Chief scientific officer George Yancopoulos talked to Scrip in an interview at the J.P. Morgan Healthcare Conference

The developer of the eye disease drug Eylea (aflibercept) and the immunology mega-blockbuster Dupixent (dupilumab) has been studying metabolic and muscle disease for more than two decades, chief scientific officer George Yancopoulos

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Atara Does An About Face As FDA Lifts Ebvallo Hold

 
• By Alaric DeArment

The biotech said it will have a type A meeting with the agency to resubmit for the cell therapy’s approval in EBV+ PTLD.